Nash Pharmaceuticals, a wholly-owned subsidiary of
Breathtec Biomedical Inc. (
CSE: BTH,
OTCQB: BTHCD,
Forum), on Monday stated that in a recently completed study, its lead compound for non-alcoholic steatohepatitis (NASH) NP-160 showed an 84% reduction of fibrosis by additional lead compound In second pre-clinical study for non-alcoholic fatty liver disease. Phase II of clinical trials look to establish human efficacy.
For more on this study,
click here.
The Company recently made news with the announcement that its team had discovered two new lead compounds for the possible new treatment of chronic kidney disease were discovered through pre-clinical product testing.
FULL DISCLOSURE: Breathtec Biomedical Inc. is a client of Stockhouse Publishing.